# Fludarabine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/fludarabine

> Fludarabine, sponsored by GILEAD SCIENCES, INC. (GILD): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | fludarabine |
| Codes |  |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | [lupus, the initial dose cohort](https://sec-api.dev/indications/lupus-the-initial-dose-cohort), [Relapsed/Refractory Mantle Cell Lymphoma](https://sec-api.dev/indications/relapsed-refractory-mantle-cell-lymphoma) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 17, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Relapsed/Refractory Mantle Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." https://clinicaltrials.gov/study/NCT04880434

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half. Indication: lupus, the initial dose cohort.
- First seen 2025-10-27, last confirmed 2026-05-04.
- SEC Form 8-K (accession 0001193125-26-202389): "In the RESET-SLE trial evaluating rese-cel without preconditioning in patients with lupus, the initial dose cohort is fully enrolled with initial data at the first dose anticipated in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1759138/000119312526202389/d110169d8k.htm
- SEC Form 8-K (accession 0001193125-26-202389): "and Cabaletta's plans to incorporate a new dose-escalation cohort into the RESET-SLE trial and the status of enrollment in the initial dose cohort of the no preconditioning cohort in the RESET-SLE trial, with initial data at the first dose anticipated in the first half of 2026;" https://www.sec.gov/Archives/edgar/data/1759138/000119312526202389/d110169d8k.htm
- SEC Form 8-K (accession 0001193125-25-250676): "Cabaletta is incorporating this new dose-escalation cohort into the RESET-SLE trial with initial clinical data anticipated in 2026." https://www.sec.gov/Archives/edgar/data/1759138/000119312525250676/caba-20251027.htm

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-07-29, last confirmed 2025-07-29.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-023689): "GeoVax expects to initiate its Phase 3 trial in 2H 2026." https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/ex_843599.htm

### August 18, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Relapsed/Refractory Mantle Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." https://clinicaltrials.gov/study/NCT04880434?tab=results

## Same indication

- [Kte-x19](https://sec-api.dev/pdufa/kte-x19) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/fludarabine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Fludarabine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/fludarabine

```bibtex
@misc{secapidev_pdufa_fludarabine_20261116,
  title        = {Fludarabine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/fludarabine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_fludarabine_20261116","title":"Fludarabine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/fludarabine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
